Cost Effectiveness Debate Now Features The Body Bag Argument
This article was originally published in The Pink Sheet Daily
Center for Medicine in the Public Interest contends that over five years, 44,000 fewer patients will be alive if ICER's cost-effectiveness calculation for multiple myeloma treatments is adopted.
You may also be interested in...
Industry communication principles offer best practices for combating contrary evidence, refuting third-party comparative effectiveness analyses and sharing real-world evidence addressing health outcomes and costs.
Institute for Clinical and Economic Review plans to unveil an updated drug value framework in early 2017.
Of the 16 products whose Orange Book patent listings have been challenged by the FTC, six have no generic competitors and two faced first generic launches this year. A review of their patent and pricing battles shows the difficulties in developing generics for these complex drugs.